Navigation Links
Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands
Date:9/21/2009

MORRISTOWN, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that G. Frederick Wilkinson has joined the Company as Executive Vice President, Global Brands. In this newly expanded position Mr. Wilkinson will be responsible for all aspects of the Company's global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product business development activities. In addition, Mr. Wilkinson will oversee Watson's biologic development efforts. Mr. Wilkinson will report directly to Paul Bisaro, President and Chief Executive Officer.

"Fred returns to Watson with an extraordinary record of accomplishments having built a successful brand products business at Duramed Pharmaceuticals, the brand business of Barr Pharmaceuticals, particularly in the area of women's healthcare," said Paul Bisaro, Watson CEO. "We will look to Fred to further strengthen our US brand business, which includes a strong product portfolio supported by the recent launches of RAPAFLO(R) and Gelnique(R)."

"Fred's global experience will also be invaluable as we seek to maximize opportunities for our brand portfolio in new markets that will result from the successful acquisition of Arrow Group, which is expected to close this fall," Bisaro added. "Finally, Fred's experience in biologics, including expansion of Barr's biopharmaceutical production capabilities, development of a pipeline of early stage projects, and his work to shepherd Barr's initial biologics vaccine product through the FDA clinical development process, will enable him to effectively guide our efforts in becoming a leader in the generic biologics area."

Most recently, Mr. Wilkinson served as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of Barr Pharmaceuticals, Inc. He joined Duramed in 2006 and had responsibility for the Company's successful expansion of Duramed's female healthcare product franchise and pipeline, and for managing Barr's biologics initiatives. Prior to joining Duramed Pharmaceuticals, Mr. Wilkinson served as President and Chief Executive Officer of Columbia Laboratories since 2001. From 1996 to 2001, Mr. Wilkinson was Senior Vice President and Chief Operating Officer of Watson Pharmaceuticals. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

For press releases and other company information, visit the Watson Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Qualitative research, which is ... a deeper understanding of the program, policy or intervention being studied. Both quantitative ... important questions. , In a new brief released today, Reading Qualitative Educational Policy ...
(Date:5/4/2016)... AZ (PRWEB) , ... May 04, 2016 , ... ... Annual Technology & Business Conference. The conference opened on Tuesday with Frank Luntz, ... discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model solution ...
(Date:5/4/2016)... MA (PRWEB) , ... May 04, 2016 , ... ... help fund Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. ... In the campaign that starts on May 3, 2016 at http://igg.me/at/EndTheVirus ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... (WOCN) Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing ... and planning tools to attendees and exhibitors for the 2016 WOCN Society & ...
(Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Actinic Keratosis ...  report to their offering.       ... Actinic Keratosis Market and Competitive Landscape Highlights ... pipeline products, Actinic Keratosis epidemiology, Actinic Keratosis ...
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
Breaking Medicine Technology: